HealthPolitics

STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/10/2026, 13:51:24 UTC.

Briefings

Lilly announced that its investigational retatrutide drug demonstrated superior efficacy in lowering blood sugar and reducing weight compared to Novo Nordisk's Ozempic in a recent head-to-head study. This finding marks a significant competitive shift in the diabetes treatment landscape, with Lilly's drug showing more pronounced effects on both metrics than the established competitor.

Key points

• Lilly's investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk's Ozempic in a head-to-head study.
• The study involved a large-scale clinical trial comparing the two drugs directly to determine their relative performance in diabetes management.

Context

This study represents a major competitive move in the diabetes treatment sector, as Lilly's retatrutide showed superior efficacy in both blood sugar control and weight reduction compared to the established Novo Nordisk competitor's Ozempic.

Limitations

The evidence is limited to a single head-to-head study comparing Lilly's retatrutide and Novo Nordisk's Ozempic. Results are based on a specific snapshot of data from this study, and the study's findings may not reflect long-term outcomes or broader clinical populations.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/10/2026, 06:31:52 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeih52e4tjckqb34ltoth54nkkyrrym7qzvtz7gfdawcvyfj5fkvg54